How a Big Pharma veteran looks to stand out in biotech as a unique ‘drug hunter’

J&J’s former head of R&D, now CEO of Parabilis Medicines, aims to remain above the biotech fray by taking on unique targets from which others have steered clear.

Biogen scores Cannes Festival win with dark humored campaign

The company’s unique campaign for a rare, terminal illness nabbed millions of views and a spot on the main stage at the Cannes Lions Festival of Creativity.

Megablockbusters are the holy grail. Here’s how drugmakers are getting there.

More drugs surpassed $10 billion in revenue last year than ever before.

Biotech’s turning point: for every challenge, an opportunity in disguise

As hurdles litter biotech’s future, forward-thinking leaders look for ways to leap to the other side.

Is DTC pharma advertising coming to an end?

A bill introduced in Congress fulfills a Trump administration goal of ending direct pharma ads to patients.

FDA to speed reviews for drugs supporting ‘national interests’

A new pilot program announced by FDA Commissioner Dr. Martin Makary would award vouchers that could cut drug reviews to one or two months — but only for products that meet a special criteria.

How a patient group tackled research diversity for one disease and triggered change for pharma

A policy win by the Foundation for Sarcoidosis Research has built momentum for other shifts that could bolster diversity in clinical trials.

Locked in a federal stalemate, states take PBM reform into their own hands

Arkansas is leading the nation in banning PBMs from owning pharmacies, as other states advance new restrictions.

Will pharma finally score a policy win for 340B?

The industry is awaiting guidance on a rebate approach to the contentious drug discount program for hospitals and aiming for tighter oversight.

A day in the life of GSK’s U.S. president

How Maya Martinez-Davis juggles life on the go during a busy year for new drug launches.

Can ‘reputational pull’ save biotech from pharma’s image problem?

A reputation is tough to build and easy to bruise. For drugmakers stuck in reputational limbo, embracing a clear direction and forward-thinking strategy can foster a rosier image.  

Pharma’s wins and losses in the budget bill

Key pharma reforms are up in the air as Republicans battle over their mammoth legislation that includes significant healthcare spending cuts.  

COVID vax restrictions may not hamper uptake — but the market is still under pressure

If insurers stop covering the shots and approvals become more restrictive, the most recent policy shifts could heap more challenges onto pharma’s vaccine space. 

The former Wall Street analyst shaping Novartis’ big-picture strategy

Ronny Gal, chief strategy and growth officer at Novartis, is guiding the company into a new era shaped by science-minded M&A and a slimmed-down pivot.

The biggest obesity deals of 2025 so far

Three pharma giants are snapping up new assets to find stronger footing in the quickly shifting weight loss market.

With ADCs on the rise, drugmakers embrace a new oncology pillar

A slow ascent for more than two decades has given way to a sharp rise in important ADC readouts, marking a milestone era for targeted treatments.

FDA’s Elsa AI is here, and the industry has questions

The agency has provided few details about its AI pilot as it makes moves on its “aggressive timeline” for rollout.  

Biotech CEO confidence hits rock bottom amid policy shifts

A new survey sheds light on the way early-stage company leaders are grappling with regulatory headwinds.

How leading oncology drugmakers set the stage for future advances

Drugmakers like J&J and Astellas are looking beyond today’s cancer treatments for the windows of opportunity decades down the road.

Sanofi to acquire Blueprint for up to $9.5B

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost to its immunology business.

COVID’s remaining biotech contenders navigate a dwindling market

With policy and funding evolving, companies are being forced to rethink strategies. 

The MAHA agenda won’t include expanding GLP-1 coverage — for now

Despite axing a Biden-era proposal for government coverage of obesity drugs, health officials have signaled a potential path forward.

AbbVie’s ADC win shows how pharma can break through in solid tumors

 An oncology pivot recently paid off for the large pharma, which scored a milestone nod for its lead ADC.

AI expertise is pharma’s next big hiring need — here’s what companies should look for

The widespread hunt for candidates who are equally versed in tech and healthcare is making AI recruiting a challenge. 

With new Alzheimer’s blood test cleared, a potential vaccine could be on the horizon

Nuravax and others are working on the next wave of Alzheimer’s treatments to catch the disease before symptoms arise.